Novartis AG (NYSE:NVS) Stock Holdings Trimmed by Diversify Advisory Services LLC

Diversify Advisory Services LLC decreased its holdings in Novartis AG (NYSE:NVS) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,592 shares of the company’s stock after selling 128 shares during the quarter. Diversify Advisory Services LLC’s holdings in Novartis were worth $455,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Legacy Investment Solutions LLC acquired a new position in Novartis during the 3rd quarter valued at about $28,000. Fortitude Family Office LLC boosted its holdings in shares of Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after acquiring an additional 267 shares in the last quarter. Clean Yield Group acquired a new position in shares of Novartis during the third quarter valued at approximately $43,000. Brooklyn Investment Group acquired a new stake in Novartis in the fourth quarter worth approximately $55,000. Finally, Beaird Harris Wealth Management LLC boosted its stake in Novartis by 280.5% during the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock valued at $81,000 after purchasing an additional 519 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Trading Up 2.2 %

Shares of NYSE NVS opened at $99.69 on Wednesday. The firm has a market capitalization of $203.76 billion, a PE ratio of 11.58, a PEG ratio of 1.34 and a beta of 0.57. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $100.44 and a two-hundred day moving average price of $108.94.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the prior year, the business earned $1.74 EPS. As a group, analysts predict that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. BMO Capital Markets upped their price objective on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.